Drug that targets scar-like tissue in tumours shows promise for pancreatic cancer

September 01, 2023

Early laboratory results in mice show the drug PXS-5505 increases survival when combined with chemotherapy in the treatment of an aggressive form of pancreatic cancer. Image: Getty ImagesA study led by the Garvan Institute of Medical Research with UNSW Sydney co-authors has revealed a new Australian drug demonstrates potential for treating pancreatic cancer. The drug targets scar-like ‘fibrotic’ tissue within tumours, and shows promise for treating pancreatic ductal adenocarcinoma, one of the most aggressive forms of pancreatic cancer with a five-year survival rate of less than 10. Potential to increase cancer survivalPancreatic cancer is often diagnosed at an advanced stage, which means chemotherapy is often the only treatment option available. In collaboration with Pharmaxis, Garvan researchers found that the drug significantly reduced fibrosis in pancreatic tumours in mouse models.

Early laboratory results in mice show the drug PXS-5505 increases survival when combined with chemotherapy in the treatment of an aggressive form of pancreatic cancer.

The drug increased survival time by more than 35 per cent in mice. Image: Getty Images

A study led by the Garvan Institute of Medical Research with UNSW Sydney co-authors has revealed a new Australian drug demonstrates potential for treating pancreatic cancer.

The drug targets scar-like ‘fibrotic’ tissue within tumours, and shows promise for treating pancreatic ductal adenocarcinoma, one of the most aggressive forms of pancreatic cancer with a five-year survival rate of less than 10.

The research in mouse models showed that when given in combination with chemotherapy, the drug PXS-5505 increased survival time by more than 35 per cent, compared to chemotherapy treatment alone.

“The preclinical validation of this first-in-class anti-fibrotic drug marks a major milestone in our quest to overcome the significant challenges in treating pancreatic cancer and brings hope to patients and their families,” says UNSW Conjoint Associate Professor Thomas Cox, head of the Matrix & Metastasis Lab at Garvan and senior author of the study, published in Nature Cancer.

Potential to increase cancer survival

Pancreatic cancer is often diagnosed at an advanced stage, which means chemotherapy is often the only treatment option available. Many pancreatic cancers develop chemotherapy resistance soon after treatment starts, which contributes to the poor survival of patients. Part of this resistance is driven by tumour fibrosis – the formation of a mesh of scar tissue-like collagen – within and around pancreatic tumours that in turn reduces the effectiveness of chemotherapy drugs.

The new drug PXS-5505, developed by Sydney-based pharmaceutical research company Pharmaxis (ASX: PXS) and currently in Phase II clinical trials for the treatment of bone marrow cancer, works by blocking a family of enzymes that are critical for the deposition of collagen into the fibrotic tissue around tumours.

In collaboration with Pharmaxis, Garvan researchers found that the drug significantly reduced fibrosis in pancreatic tumours in mouse models.

The combination therapy also substantially reduced the spread of the cancer to other organs, such as the liver, by 45 per cent.

Associate Professor Thomas Cox and Dr Jessica Chitty. Photo: Garvan Institute of Medical Research

“PXS-5505 returns the tumour microenvironment to a more ‘normal’ state by reducing fibrosis and decreasing tumour stiffness,” explains UNSW Conjoint Associate Lecturer Dr Jessica Chitty, Senior Research Officer at Garvan and first author of the study. “This allows chemotherapy drugs to penetrate the tumours more easily, work more effectively, and destroy more cancer cells.”

“PXS-5505 shows real potential to improve chemotherapy for patients,” says A/Prof. Cox. “We are now in the process of progressing this work toward clinical trials that will evaluate this promising drug combination approach for pancreatic cancer patients.”

“Pharmaxis has already seen very promising early results in a Phase II trial with patients that have the bone marrow cancer myelofibrosis,” commented Gary Phillips, CEO of Pharmaxis. “This groundbreaking research stems from a long collaboration with the team of high calibre researchers at the Garvan Institute and provides exciting new evidence that PXS-5505 may also have a role as a therapy to improve the effect of current chemotherapy drugs in solid tumours like pancreatic cancer and extending the life of patients.”

The source of this news is from University of New South Wales

Popular in Research

1

1 week ago

Scientists use generative AI to answer complex questions in physics

2

Jun 28, 2024

HKUST researchers uncover mechanism for short-distance vesicle movements | The Hong Kong University of Science and Technology

3

Jun 28, 2024

Birth by C-section more than doubles odds of measles vaccine failure

4

Jun 29, 2024

This sound-suppressing silk can create quiet spaces

5

1 week ago

First language song book a hit in the APY Lands

Biden’s ABC Interview Was a Necessary Appointment With the Public — and a Botched One

1 week ago

No “Serious Condition”: Watch Biden Tell George Stephanopoulos Of Debate Debacle In First Clip From ABC Interview

Jul 6, 2024

American Air, Gate Gourmet Face Pressure on Contracts to Avoid Strikes

1 week ago

MSN

1 week ago

NYU Dentistry Names Implant Dentistry Fellowship in Recognition of Major Gift from Alumni Noel Liu and Nazish Jafri

1 week ago

Biden Aides Provided Questions in Advance for His Radio Interviews

1 week ago